Corporate Profile

Sensei is a biopharmaceutical company engaged in the discovery, development, and delivery of next-generation immunotherapies for the treatment of cancer. The company is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases. The company’s research is dedicated to two immuno-oncology platforms: Tumor Microenvironment Antibody biologics, or TMAb™ platform and ImmunoPhage™ platform and Phortress™ library.

Sensei’s TMAb platform is comprised of human monoclonal antibodies and alpaca-derived nanobodies selectively active in the tumor microenvironment. The lead product candidate, SNS-101, is in preclinical studies targeting the novel immune checkpoint regulator V-set Immunoglobulin Domain Ig Suppressor or T cell activation, or VISTA. SNS-101 is a potent, pH-dependent fully human monoclonal antibody designed to block the interaction of VISTA with its receptor, PSGL-1. Discovery efforts are also underway directed toward the V-Set And Immunoglobulin Domain Containing 4, or VSIG4, a potent inhibitor of T cell activity, often overexpressed on macrophages within the tumor microenvironment.

Sensei’s proprietary ImmunoPhage platform leverages the self-adjuvanted and highly immunogenic properties of engineered bacteriophage. This platform allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. The program includes SNS-401-NG, a preclinical candidate for the treatment of Merkel cell carcinoma

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference

BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will present at the Jefferies

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of 2025 with $136.2 million on hand at end of first quarter 2022 - BOSTON, May 10, 2022 (GLOBE NEWSWIRE)

Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights

- Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA - - Initiated 2 new therapeutic programs and IND-enabling studies with SNS-101, a tumor-selective anti-VISTA antibody product candidate from TMAb platform - -